​​​The Leukemia Site Group at Princess Margaret is the only acute leukemia centre in the Greater Toronto Area. It is also the largest comprehensive leukemia program in Canada. The Leukemia Site Group is breaking new ground in the diagnosis, treatment and management of this complex malignancy.

The leukemia program at Princess Margaret also collaborates with numerous international ground-breaking basic, preclinical and clinical leukemia research initiatives. Our goal is to improve leukemia diagnosis and care, and to offer the best treatment possible to our patients.

Leukemia Tissue Bank

The Leukemia Tissue Bank at Princess Margaret Cancer Centre collects and stores samples from consented patients with a variety of hematologic disorders and other malignancies. High quality samples including viable cells, plasma and serum are available to qualified researchers at University Health Network, at academic centres around the world, and to industry. Learn more about the Leukemia Tissue Bank at Princess Margaret Cancer Centre »

Clinical Trials

At any one time, the leukemia program runs about 30 clinical trials. These include investigator-initiated, company-sponsored and cooperative-group-supported Phase I, II and III trials. No other Canadian leukemia centre has access to such a variety of trials.

Open Clinical Trials

 
NCT and Other Names
 
Title
 
Principal Investigator
 
Disease Location
Acute Lymphoblastic Leukemia
NCT06137118
D7405C00001
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic LeukaemiaDr. Andre SchuhAcute Lymphoblastic Leukemia
NCT04994717
20190360, 2023-503640-14
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic LeukemiaDr. Andre SchuhAcute Lymphoblastic Leukemia
Acute Myelogenous Leukemia
NCT04811560
CR108998, 75276617ALE1001,2023-506581-31-00
A Phase 1/2 Study of Bleximenib in Participants With Acute LeukemiaDr. Andre SchuhAcute Myelogenous Leukemia
NCT06226571
SNDX-5613-0708, 2024-514531-18-00
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid LeukemiasDr. Andre SchuhAcute Myelogenous Leukemia
NCT05907057
DIM-95031-006, 2022-501709-11
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.Dr. Andre SchuhAcute Myelogenous Leukemia
Chronic Myeloid Leukemia
NCT05304377
ELVN-001-101
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid LeukemiaDr. Dennis KimChronic Myeloid Leukemia
NCT06384261
OV-AML-1231
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive TherapyDr. Karen YeeChronic Myeloid Leukemia
NCT06423911
HQP1351CG301
Study of Olverembatinib (HQP1351) in Patients With CP-CMLDr. Dennis KimChronic Myeloid Leukemia
Multiple Sites
NCT04256317
ASTX030-01
A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AMLDr. Guillaume Richard-CarpentierMultiple Sites
NCT04730258
TWT-202
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMMLDr. Karen YeeMultiple Sites
NCT06150157
88549968MPN1001, 88549968MPN1001,2023-505584-36-00
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative NeoplasmsDr. Vikas GuptaMultiple Sites
NCT06618001
89853413AML1001, 89853413AML1001,2024-513199-16-00
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic NeoplasmsDr. Guillaume Richard-CarpentierMultiple Sites
NCT04224974
SC26
Emotion and Symptom-Focused Engagement Trial for Individuals With Acute LeukemiaDr. Gary RodinMultiple Sites
NCT03168815
vSep2016
Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic BronchoscopyDr. Lorenzo Del SorboMultiple Sites
NCT04279847
INCB 57643-103, 2023-506145-38-00,2020-003532-25
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid NeoplasmsDr. Vikas GuptaMultiple Sites
NCT06419634
CA235-0001, 2024-519537-29
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeDr. Andre SchuhMultiple Sites
NCT04260022
HQP1351CU101
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALLDr. Dennis KimMultiple Sites
NCT03816319
NCI-2019-00238, NCI-2019-00238,10237,10237,UM1CA186644
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased BlastsDr. Guillaume Richard-CarpentierMultiple Sites
NCT05600894
NCI-2022-08797, NCI-2022-08797,10538,10538,UM1CA186689
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative NeoplasmDr. Marta DavidsonMultiple Sites
Myelodysplastic Syndrome (MDS)
NCT06499285
KER-050-D301
The Efficacy and Safety of Elritercept in Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Anemia (RENEW)Dr. Karen YeeMyelodysplastic Syndrome (MDS)
 
Page of 2
View 1 - 20 of 28

To refer a patient to a clinical trial, complete a new patient referral form. Learn more about the Princess Margaret referral process »

For patients: Are you considering taking part in a clinical trial? Learn more about how and why clinical trials are done and what you can expect if you decide to take part in a trial »

https://www.uhn.ca/PrincessMargaret/Education/Continuing_Education_Programs/Pages/continuing_education_programs.aspx
Last reviewed: 11/6/2024
Last modified: 11/7/2024 5:44 AM
Back to Top